1. Search Result
Search Result
Results for "

Cos-7

" in MedChemExpress (MCE) Product Catalog:

27

Inhibitors & Agonists

2

Fluorescent Dye

5

Peptides

3

MCE Kits

3

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W011121

    GPR119 Metabolic Disease
    2-Oleoylglycerol is a dietary naturally occurring lipid. 2-Oleoylglycerol is a GPR119 agonist, with an EC50 of 2.5 μM for human GPR119 in transiently transfected COS-7 cells. 2-Oleoylglycerol stimulates glucagon-like peptide-1 (GLP-1) secretion in vivo .
    2-Oleoylglycerol
  • HY-N2337
    11beta-Hydroxyprogesterone
    2 Publications Verification

    11β-Hydroxyprogesterone

    Endogenous Metabolite Cardiovascular Disease
    11beta-Hydroxyprogesterone is a potent inhibitors of 11β-Hydroxysteroid dehydrogenase; also activates human mineralocorticoid receptor in COS-7 cells with an ED50 of 10 nM.
    11beta-Hydroxyprogesterone
  • HY-W011243

    Others Cardiovascular Disease
    11alpha-Hydroxyprogesterone is the analogue of 11beta-Hydroxyprogesterone (HY-N2337), and can be used as an experimental control. 11beta-Hydroxyprogesterone is a potent inhibitors of 11β-Hydroxysteroid dehydrogenase; also activates human mineralocorticoid receptor in COS-7 cells with an ED50 of 10 nM.
    11alpha-Hydroxyprogesterone
  • HY-12242

    Dopamine Transporter Neurological Disease
    GBR 12935 dihydrochloride is a potent, and selective dopamine reuptake inhibitor, with the binding constant (Kd) of 1.08 nM in COS-7 cells. GBR 12935 dihydrochloride stimulates the locomotion activity in different mice strains but fails to induce stereotypy. Thus, GBR 12935 dihydrochloride also prevents the d-Fenfluramine-induced head-twitch response in mice .
    GBR 12935 dihydrochloride
  • HY-12242A

    Dopamine Transporter Neurological Disease
    GBR 12935 is a potent, and selective dopamine reuptake inhibitor, with the binding constant (Kd) of 1.08 nM in COS-7 cells. GBR 12935 stimulates the locomotion activity in different mice strains but fails to induce stereotypy. Thus, GBR 12935 also prevents the d-Fenfluramine-induced head-twitch response in mice .
    GBR 12935
  • HY-107500
    UVI 3003
    3 Publications Verification

    RAR/RXR Autophagy Others
    UVI 3003 is a highly selective antagonist of retinoid X receptor (RXR), and inhibits xenopus and human RXRα in Cos7 cells, with IC50s of 0.22 and 0.24 μM, respectively.
    UVI 3003
  • HY-B0563B
    Ropivacaine hydrochloride
    4 Publications Verification

    Sodium Channel Potassium Channel Cardiovascular Disease Neurological Disease Cancer
    Ropivacaine hydrochloride is a potent sodium channel blocker and blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese . Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane . Ropivacaine is widely used for neuropathic pain management in vivo .
    Ropivacaine hydrochloride
  • HY-B0563
    Ropivacaine
    4 Publications Verification

    Sodium Channel Potassium Channel Cardiovascular Disease Neurological Disease
    Ropivacain is a potent sodium channel blocker. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese . Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane . Ropivacaine is used for the research of neuropathic pain management .
    Ropivacaine
  • HY-B0563A
    Ropivacaine hydrochloride monohydrate
    4 Publications Verification

    Sodium Channel Potassium Channel Cardiovascular Disease Neurological Disease
    Ropivacaine hydrochloride monohydrate is a potent sodium channel blocker and blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese . Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane . Ropivacaine is widely used for regional anesthesia and neuropathic pain management in vivo .
    Ropivacaine hydrochloride monohydrate
  • HY-152205

    Myosin Others
    JB061 is a nonmuscle myosin inhibitor with IC50s of 4.4 μM (Cardiac muscle myosin), 9.1 μM (Skeletal muscle myosin), and >100 μM (Smooth muscle myosin II), respectively. JB061 poorly decreases ATPase activity (IC50>200 μM). JB061 shows cytotoxicity against COS-7 cells with an IC50 value of 39 μM .
    JB061
  • HY-B0563C
    Ropivacaine mesylate
    4 Publications Verification

    Sodium Channel Potassium Channel Cardiovascular Disease Neurological Disease
    Ropivacaine mesylate is a long-acting amide local anaesthetic agent for a spinal block and effectively blocks neuropathic pain. Ropivacaine blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibressup>[1] . Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane .
    Ropivacaine mesylate
  • HY-B0563S1

    Isotope-Labeled Compounds Sodium Channel Potassium Channel Cardiovascular Disease Neurological Disease
    Ropivacaine-d7 is deuterium labeled Ropivacaine. Ropivacain is a potent sodium channel blocker. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese[1][2]. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane[3]. Ropivacaine is used for the research of neuropathic pain management[1].
    Ropivacaine-d<em>7</em>
  • HY-B0563BS

    Isotope-Labeled Compounds Neurological Disease
    Ropivacaine-d7 hydrochloride is a deuterium labeled Ropivacaine (hydrochloride) (HY-B0563B) . Ropivacaine hydrochloride is a potent?sodium channel?blocker and blocks impulse conduction via reversible inhibition of?sodium ion influx?in nerve fibrese . Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane . Ropivacaine is widely used for neuropathic pain?management in vivo .
    Ropivacaine-d<em>7</em> hydrochloride
  • HY-P1432A

    GHSR
    K-(D-1-Nal)-FwLL-NH2 TFA is a high affinity and potent ghrelin receptor inverse agonist (Ki values are 4.9 and 31 nM in COS7 and HEK293T cells, respectively). K-(D-1-Nal)-FwLL-NH2 blocks ghrelin receptor-mediated Gq- and G13-dependent signaling pathways.
    K-(D-1-Nal)-FwLL-NH2 TFA
  • HY-108573
    P-1075
    1 Publications Verification

    Potassium Channel Cardiovascular Disease
    P-1075 is a potent activator of sulfonylurea receptor 2-associated ATP-sensitive potassium channels (SUR2-KIR6), with an EC50 value of 45 nM for SUR2B-KIR6 channel activation . P-1075 also P1075 opens mitochondrial K(ATP) channels and generates reactive oxygen species resulting in cardioprotection of rabbit hearts .
    P-1075
  • HY-P2542

    Insulin Receptor Metabolic Disease
    GIP (3-42), human acts as a glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist, moderating the insulin secreting and metabolic actions of GIP in vivo .
    GIP (3-42), human
  • HY-108480

    Neurokinin Receptor Neurological Disease
    SDZ NKT 343 is a selective, orally active NK1 receptor antagonist with an IC50 of 0.62 nM against human NK1 receptor. SDZ NKT 343 has good analgesic activity .
    SDZ NKT 343
  • HY-103371
    DCPIB
    5 Publications Verification

    Chloride Channel Potassium Channel Neurological Disease
    DCPIB is a selective, reversible and potent inhibitor of volume-regulated anion channels (VRAC). DCPIB voltage-dependently activates potassium channels TREK1 and TRAAK, and inhibits TRESK, TASK1 and TASK3 (IC50s: 0.14, 0.95, 50.72 μM, respectively). DCPIB is also a selective blocker of swelling-induced chloride current (ICl,swell), with an IC50 of 4.1 μM. DCPIB is a useful tool for investigating structure-function studies of K2P channels .
    DCPIB
  • HY-N6682
    Cytochalasin D
    Maximum Cited Publications
    40 Publications Verification

    Zygosporin A; NSC 209835

    Arp2/3 Complex Antibiotic YAP Infection
    Cytochalasin D (Zygosporin A) is a potent actin polymerization inhibitor, could be derived from fungus. Cytochalasin D has cell-permeable activity. Cytochalasin D inhibits the G-actin–cofilin interaction by binding to G-actin. Cytochalasin D also inhibits the binding of cofilin to F-actin and decreases the rate of both actin polymerization and depolymerization in living cells. Cytochalasin D can reduce exosome release, in turn reducing the amount of survivin present in the tumour environment. Cytochalasin D induces phosphorylation and cytoplasmic retention of Yap .
    Cytochalasin D
  • HY-P1422

    Potassium Channel 5-HT Receptor Neurological Disease
    Spadin, a natural peptide derived from a propeptide released in blood, is a potent TREK-1 channel blocker with IC50 value of 10 nM. Spadin enhances dorsal raphe nucleus 5-HT neurotransmission in mice and induces hippocampal CREB activation and neurogenesis. Spadin can be used for antidepressant research .
    Spadin
  • HY-P1422A
    Spadin TFA
    1 Publications Verification

    Potassium Channel 5-HT Receptor Neurological Disease
    Spadin TFA, a natural peptide derived from a propeptide released in blood, is a potent TREK-1 channel blocker with an IC50 value of 10 nM. Spadin TFA enhances dorsal raphe nucleus 5-HT neurotransmission in mice and induces hippocampal CREB activation and neurogenesis. Spadin TFA can be used for antidepressant research .
    Spadin TFA
  • HY-128206
    I3MT-3
    4 Publications Verification

    HMPSNE

    Hippo (MST) Metabolic Disease
    I3MT-3 (HMPSNE) is a potent, selective, and cell-membrane permeable inhibitor of 3-Mercaptopyruvate sulfurtransferase (3MST) (IC50=2.7 μM). I3MT-3 is inactive for other H2S/sulfane sulfur-producing enzymes. I3MT-3 targets a persulfurated cysteine residue located in the active site of 3MST .
    I3MT-3
  • HY-121885
    LMD-009
    1 Publications Verification

    CCR Metabolic Disease Endocrinology
    LMD-009 is a selective CCR8 nonpeptide agonist. LMD-009 mediates chemotaxis, inositol phosphate accumulation, and calcium release in high potencies with EC50s from 11 to 87 nM .
    LMD-009
  • HY-D1606

    Adrenergic Receptor Metabolic Disease
    BODIPY FL prazosin is a fluorescent α1-adrenergic antagonist with Ki values of 14.5, 43.3 nM for α1a-AR and α1b-AR, respectively. BODIPY FL prazosin also is a fluorescent ligand with the excitation and emission wavelengths are 485 and 535 nm, respectively. BODIPY FL prazosin can be used for study the differences in the subcellular localization of α1-adrenoceptor subtypes .
    BODIPY FL prazosin
  • HY-152206

    Myosin Neurological Disease
    JB062 is a nonmuscle myosin inhibitor with IC50 values of 1.6, 5.4, and >100 μM for Skeletal muscle myosin, Cardiac muscle myosin, and Smooth muscle myosin II, respectively. JB062 has cytotoxic to human cancer cells but not normal cells. JB062 can be used in research of muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy .
    JB062
  • HY-133523

    Fluorescent Dye Cancer
    HBC514 is a nonfluorescent HBC-analog but emits strong green fluorescence upon forming a tight complex with Pepper RNA aptamer. HBC514-Pepper complex enables visualization of RNAs and the fluorescences can be altered flexibly by simple washing and staining in living Pepper-tagged cells[1].
    HBC514
  • HY-163340

    Glucocorticoid Receptor Androgen Receptor Cancer
    GA32 (compound 58r) is potent androgen receptor (AR)/glucocorticoid receptor (GR) dual inhibitor with IC50 values of 0.13 μM and 0.83 μM for AR and GR, respectively. GA32 inhibits the proliferation of Enzalutamide (HY-70002) resistance castration-resistant prostate cancer both in vitro and in vivo .
    GA32

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: